Table 2.
Between-group Comparison of Changes from Baseline to 10-Week Post Intervention
| Baseline |
10 weeks |
p value | Cohen's d | |||
|---|---|---|---|---|---|---|
| Experimental (n = 10) | Control (n = 10) | Experimental (n = 10) | Control (n = 10) | |||
| Pain | ||||||
| SMPQ | 5.8 ± 1.7 | 7 ± 1.8 | 3.6 ± 2.3 | 6.4 ± 1.9 | 0.01** | 1.26 |
| PPT | 572 ± 173 | 747 ± 181 | 782 ± 196 | 750 ± 452 | 0.06 | 0.74 |
| VAS | 5.9 ± 1.4 | 7 ± 1.5 | 3.1 ± 1.7 | 6.8 ± 2.1 | 0.05* | 1.58 |
| Sleep quality | 9.7 ± 2.5 | 12.2 ± 4.2 | 6 ± 3.3 | 11.3 ± 4.9 | 0.01** | 1.6 |
| Fatigue | 6.9 ± 2.1 | 7.1 ± 2 | 4.3 ± 2.8 | 6.4 ± 2.6 | 0.05* | 0.8 |
| FM impact | 52.1 ± 18.5 | 57.6 ± 16.7 | 32.5 ± 19.6 | 50.5 ± 21.2 | 0.01** | 1.17 |
| Depression | 7.4 ± 3.4 | 7.3 ± 4.9 | 4.2 ± 3.4 | 6.5 ± 4.6 | 0.05* | 0.84 |
| Anxiety | 11.4 ± 3.7 | 7.8 ± 5.5 | 7.4 ± 3.2 | 6.3 ± 4.4 | 0.05* | 0.89 |
| QOL | 76.1 ± 16.5 | 69.8 ± 21.1 | 79.4 ± 15.4 | 84.6 ± 8.8 | 0.05*• | 0.81 |
The values are shown in mean ± standard deviation.
**
Indicates statistical significance at P < 0.01.
*
Indicates statistical significance at P < 0.05
• Indicates that the control group presented superior improvement than the experimental group.
FM, fibromyalgia; PPT, pressure pain threshold; QOL, quality of life; SMPQ, Short-Form McGill Pain Questionnaire; VAS, visual analog scale.